The management of schizophrenia: Focus on extended-release quetiapine fumarate

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 549-564

  Peuskens, Joseph ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Adherence; Adverse events; Atypical antipsychotics

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; NORQUETIAPINE; PLACEBO; PROLACTIN; QUETIAPINE; UNCLASSIFIED DRUG;

AGITATION; AKATHISIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EVENING DOSAGE; EXTENDED RELEASE FORMULATION; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HEART RATE; HUMAN; HYPOTENSION; IMMEDIATE RELEASE FORMULATION; INSOMNIA; LETHARGY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; RECEPTOR AFFINITY; RELAPSE; REMISSION; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; STOMACH DISCOMFORT; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREMOR; VOMITING; WEIGHT; WEIGHT GAIN; XEROSTOMIA;

EID: 80855166579     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s3380     Document Type: Article

References (82)

1. Weiden PJ, Preskorn SH, Fahnestock PA, Carpenter D, Ross R, Docherty JP. Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap. J Clin Psychiatry. 2007;68 Suppl 7:1-48.
2. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
3. Valenstein M, Ganoczy D, McCarthy JF, Myra KH, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006; 67(10):1542-1550.
4. Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv. 2003;54(5):665-667.
5. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am. 2007;30(3): 437-452.
6. Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001;158(11): 1835-1842.
7. Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry. 2006;67(7): 1114-1123.
8. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006; 67 Suppl 5:3-8.
9. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184:346-351.
10. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325-351.
11. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34(1):173-180.
12. Fleischhacker WW, Hofer A, Hummer M. Managing Schizophrenia: the compliance challenge. Current Medicine Group; 2007.
13. Hudson TJ, Owen RR, Thrush CR, et al. A pilot study of barriers to medication adherence in schizophrenia. J Clin Psychiatry. 2004;65(2): 211-216.
14. Masand PS, Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol. 2006;1(1):47-56.
15. Jonsdottir H, Friis S, Horne R, Pettersen KI, Reikvam A, Andreassen OA. Beliefs about medications: measurement and relationship to adherence in patients with severe mental disorders. Acta Psychiatr Scand. 2009; 119(1):78-84.
16. Tandon R, Marcus R, Stock E, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA). Schizophr Res. 2006;84(1):77-89.
17. Kikkert MJ, Schene AH, Koeter MW, et al. Medication adherence in schizophrenia: exploring patients', carers' and professionals' views. Schizophr Bull. 2006;32(4):786-794.
18. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a f irst episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008; 69(1):106-113.
19. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia [updated 2004]. Available from: http://www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=Schizophrenia2ePG_05-15-06. Accessed January 21, 2010.
20. National Institute of Clinical Excellence. Core interventions in the treatment and management of schizophrenia in primary and secondary care (Clinical Guideline 1) [updated 2004 Apr 12]. Available from: http://www.nice.org.uk.
21. Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry. 2002;14(2):123-129.
22. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21(11): 911-936.
23. De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101(1-3):295-303.
24. Arango C, Bobes J. Managing acute exacerbations of schizophrenia: focus on quetiapine. Curr Med Res Opin. 2004;20(5):619-626.
25. Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin. 2004;20(9):1357-1363.
26. Hellewell JSE, Cameron-Hands D, Cantillon M. Seroquel®: evidence for efficacy in the treatment of hostility and aggression. Schizophr Res. 1998;29:154-155.
27. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med. 2009;39(10): 1591-1602.
28. Seroquel® (quetiapine fumarate) tablets - US prescribing information. [updated 2010]. Available from: http://www1.astrazeneca-us.com/pi/seroquel.pdf. Accessed January 18, 2010.
29. Astra Zeneca. Seroquel XR (quetiapine fumarate) extended release tablets - US prescribing information [updated 2011 Mar]. Available from: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf. Accessed May 5, 2011.
30. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121(1-2):106-115.
31. Peuskens J, Trivedi JK, Malyarov S, et al. Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized placebo-controlled trial in clinically stable patients. Psychiatry (Edgemont). 2007;4(11):34-50.
32. Seroquel XR (quetiapine fumarate) Extended-Release Tablets - US prescribing information. [updated 2010]. Available from: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf. Accessed April 23, 2010.
33. Zeneca. Seroquel XR - Summary of product characteristics [updated 2010]. Available from: http://www.medicines.ie/medicine/13032/SPC/Seroquel+XR+50mg%2c+200mg%2c+300mg%2c+400mg+prolonged-release+tablets/. Accessed March 5, 2010.
34. Zeneca. Seroquel XR and seroquel approved in europe for prevention of recurrence of bipolar disorder [updated 2009]. Available from: http://www.astrazeneca.com/media/latest-press-releases/2009/Seroquel_Bipolar_Maint_EU?itemId=7082393. Accessed January 21, 2010.
35. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13(7):917-932.
36. Bortnick B, El-Khalili N, Banov M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study. J Affect Disord. 2011;128(1-2):83-94.
37. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4): 540-549.
38. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Åström M, Brecher M. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009;70(4):526-539.
39. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009;14(6):299-313.
40. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26(1):11-24.
41. Merideth C, Cutler A, Neijber A, She F, Eriksson HA. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalised anxiety disorder (GAD). Eur Neuropsychopharmacol. 2008;18:S499.
42. Bandelow B, Chouinard G, Bobes J, et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010;13:305-320.
43. Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011;31: 418-428.
44. Zeneca. Seroquel XR recommended for approval in EU as an add-on treatment of major depressive disorder [updated 2010]. Available from: http://www.astrazeneca.com/media/latest-press-releases/ seroquelXR-MDD?itemId=9260911. Accessed April 23, 2010.
45. Zeneca. US FDA approves seroquel XR for add-on treatment of major depressive disorder [updated 2009]. Available from AstraZeneca. Accessed January 21, 2010.
46. Figueroa C, Brecher M, Hamer-Maansson JE, Winter H. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(2):199-204.
47. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40(7):509-522.
48. Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry. 2002;63(Suppl 13):5-11.
49. Datto C, Berggren L, Patel J, Eriksson HA. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjects. Clin Ther. 2009;31:492-502.
50. Juckel G, Winter HR, Ståhle L, Miller F, Strid S. The pharmacokinetics of extended release quetiapine fumarate are not affected by a light meal. Poster presented at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, Montreux, Switzerland, February 3-7, 2008.
51. Goldstein JM, Christoph G, Grimm S, Liu J, Widzowski D, Brecher M. Quetiapine's antidepressant properties: direct and indirect pharmacologic actions on norepinephrine and serotonin receptors. Eur Neuropsychopharmacol. 2007;17(Suppl 4):S401.
52. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27-38.
53. Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'? Clin Neurosci Res. 2003;3:108-117.
54. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000;25(2):161-166.
55. Nyberg S, Zukin S. PET-measured occupancy of the D2 receptor: a comparison of quetiapine fumarate immediate- and extended-release formulations in healthy subjects. Poster presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, Florida, USA, December 6-10, 2009.
56. Nyberg S, Widzowski D. Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties. Eur Psychiatry. 2010;25:1446.
57. Nyberg S, Takano A, Grimm S, et al. PET-measured D2, 5-HT2, and norepinephrine transporter (NET) occupancy by quetiapine and N- desalkyl-quetiapine in non-human primates. Eur Neuropsychopharmacol. 2007;17(Suppl 4):S254-S255.
58. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, Rothman RB, Roth BL. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology. 2008; 33(10):2303-2312.
59. Mamo DC, Uchida H, Vitcu I, et al. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. J Clin Psychiatry. 2008;69(1):81-86.
60. Pillai A, Terry AV Jr, Mahadik SP. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr Res. 2006;82(1):95-106.
61. Fumagalli F, Molteni R, Bedogni F, et al. Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. NeuroReport. 2004;15(13):2109-2112.
62. Xu H, Qing H, Lu W, Keegan D, Richardson JS, Li X-M. NR72: quetiapine attenuates the immobilization-induced decrease of BDNF in rat hippocampus. Poster presented at the American Psychiatric Association, Philadelphia, Pennsylvania, USA, May 18-23, 2002.
63. Ganesan S, Agambaram V, Randeree F, Eggens I, Huizar K, Meulien D. Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin. 2008;24(1):21-32.
64. Kahn RS, Schulz SC, Palazov VD, et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):832-842.
65. Lindenmayer JP, Brown D, Liu S, Brecher M, Meulien D. The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study. Psychopharmacol Bull. 2008; 41(3):11-35.
66. Moller HJ, Johnson S, Mateva T, et al. Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. Int Clin Psychopharmacol. 2008;23(2):95-105.
67. Cutler AJ, Tran-Johnson T, Kalali A, Astrom M, Brecher M, Meulien D. A failed 6-week, randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned. Psychopharmacol Bull. 2010; 43(4):37-69.
68. Kalali A, Schulz SC, Kahn RS, et al. Effectiveness of once-daily extended release quetiapine fumarate (quetiapine XR) for excitability, hostility and aggression in schizophrenia. Poster 4002 presented at the 161st Annual Meeting of the American Psychiatric Association, Washington, DC, USA, May 3-8, 2008.
69. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209-1222.
70. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162(3):441-449.
71. Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry. 2006;39(5):161-170.
72. Peuskens J, Trivedi JK, Brecher M, Miller F. Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo- controlled study. Int Clin Psychopharmacol. 2010;25: 183-187.
73. Meulien D, Huizar K, Brecher M. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Hum Psychopharmacol. 2010;25(2):103-115.
74. Boidi G, Ferro M. Rapid dose initiation of quetiapine for the treatment of acute schizophrenia and schizoaffective disorder: a randomised, multicentre, parallel-group, open study. Hum Psychopharmacol. 2007; 22(5):299-306.
75. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22-e33.
76. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006; 67(3):453-460.
77. Knapp M, King D, Pugner K, Lapuerta P. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry. 2004;184:509-516.
78. Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry. 2008;69(2):302-309.
79. Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007;90(1-3):186-197.
80. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebocontrolled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010; 71(2):163-174.
81. Young AH, McElroy SL, Bauer M, et al. A double-blind, placebocontrolled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010;71(2):150-162.
82. Haro JM, Novick D, Suarez D, Alonso J, Lepine JP, Ratcliffe M. Remission and relapse in the outpatient care of schizophrenia: three-year results from the schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2006;26(6):571-578.